Get the Stockscreener App
69.20
0.87%
0.57
Monopar Therapeutics Inc stock is traded at $69.20, with a volume of 30,814.
It is up +0.87% in the last 24 hours and down -24.39% over the past month.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
See More
Previous Close:
$68.63
Open:
$68.55
24h Volume:
30,814
Relative Volume:
0.22
Market Cap:
$466.95M
Revenue:
-
Net Income/Loss:
$-7.12M
P/E Ratio:
-30.09
EPS:
-2.3
Net Cash Flow:
$-6.82M
1W Performance:
-7.84%
1M Performance:
-24.39%
6M Performance:
+110.68%
1Y Performance:
+168.13%
1-Day Range:
$68.37
$70.04
1-Week Range:
$64.25
$75.21
52-Week Range:
$21.00
$105.00
Monopar Therapeutics Inc Stock (MNPR) Company Profile
Name
Monopar Therapeutics Inc
Sector
Industry
Phone
(847) 388-0349
Address
1000 SKOKIE BLVD SUITE 350, WILMETTE
Compare MNPR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MNPR
Monopar Therapeutics Inc
|
69.88 | 458.63M | 0 | -7.12M | -6.82M | -2.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.22 | 115.75B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.00 | 80.71B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
410.70 | 52.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
854.66 | 52.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.99 | 37.29B | 447.02M | -1.18B | -906.14M | -6.1812 |
Monopar Therapeutics Inc Stock (MNPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-14-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Nov-10-25 | Initiated | Leerink Partners | Outperform |
| Oct-13-25 | Initiated | Barclays | Overweight |
| Sep-09-25 | Initiated | BTIG Research | Buy |
| Sep-03-25 | Initiated | Oppenheimer | Outperform |
| Sep-03-25 | Initiated | Raymond James | Strong Buy |
| Aug-26-25 | Resumed | H.C. Wainwright | Buy |
| Jul-07-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-23-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-19-25 | Resumed | Piper Sandler | Overweight |
| Jan-10-25 | Initiated | Piper Sandler | Overweight |
| Oct-11-24 | Initiated | Rodman & Renshaw | Buy |
| Jan-28-21 | Initiated | ROTH Capital | Buy |
View All
Monopar Therapeutics Inc Stock (MNPR) Latest News
What Awaits These 4 Biotech Stocks That More Than Doubled in 2025 - Zacks Investment Research
Independent Director Arthur Klausner Sold A Bunch Of Shares In Monopar Therapeutics - simplywall.st
What dividend safety score for Monopar Therapeutics Inc. stockStop Loss & AI Powered Buy and Sell Recommendations - Улправда
Major Insider Move Shakes Up Investor Watch on Monopar Therapeutics - TipRanks
Is Monopar Therapeutics Inc. stock a safe haven assetJuly 2025 Summary & Accurate Intraday Trading Signals - Улправда
Insider Sell: Arthur Klausner Sells Shares of Monopar Therapeuti - GuruFocus
Monopar Therapeutics Insider Sold Shares Worth $343,889, According to a Recent SEC Filing - marketscreener.com
Will Monopar Therapeutics Inc. stock gain from strong economyWeekly Stock Report & Weekly High Conviction Ideas - DonanımHaber
Why retail investors favor Monopar Therapeutics Inc. stock2025 Momentum Check & Community Shared Stock Ideas - DonanımHaber
Why Monopar Therapeutics Inc. stock appeals to analystsJuly 2025 PreEarnings & High Return Stock Watch Alerts - DonanımHaber
Is Monopar Therapeutics Inc. (1IY0) stock a good hedge against inflation2025 Retail Activity & Technical Buy Zone Confirmation - DonanımHaber
How cyclical is Monopar Therapeutics Inc. (1IY0) stock compared to rivalsDip Buying & High Conviction Trade Alerts - Улправда
Treasury Yields: How cyclical is Monopar Therapeutics Inc. (1IY0) stock compared to rivalsInsider Buying & Community Verified Trade Signals - Улправда
(MNPR) Movement Within Algorithmic Entry Frameworks - news.stocktradersdaily.com
Monopar Therapeutics (NASDAQ:MNPR) Rating Increased to Hold at Wall Street Zen - Defense World
Monopar Therapeutics Inc. (NASDAQ:MNPR) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Monopar Therapeutics Inc. (NASDAQ:MNPR) Given Average Recommendation of “Buy” by Brokerages - Defense World
Monopar Therapeutics (NASDAQ:MNPR) Upgraded at Wall Street Zen - Defense World
Aug Catalysts: How interest rate cuts could boost Monopar Therapeutics Inc stockGap Up & High Accuracy Trade Alerts - moha.gov.vn
Monopar Therapeutics (NASDAQ:MNPR) Shares Up 6.3%Should You Buy? - MarketBeat
Monopar Therapeutics (NASDAQ:MNPR) Downgraded to Sell Rating by Wall Street Zen - MarketBeat
Will Monopar Therapeutics Inc. stock benefit from commodity prices2025 Winners & Losers & Safe Swing Trade Setup Alerts - Newser
Will Monopar Therapeutics Inc. (1IY0) stock rise with strong economyShare Buyback & Free Weekly Watchlist of Top Performers - Newser
How Monopar Therapeutics Inc. (1IY0) stock behaves in tightening cyclesJuly 2025 Setups & Consistent Growth Equity Picks - Newser
Is Monopar Therapeutics Inc. (1IY0) stock a safe buy pre earningsJuly 2025 Gainers & Verified Technical Signals - Newser
How (MNPR) Movements Inform Risk Allocation Models - news.stocktradersdaily.com
Monopar Therapeutics (NASDAQ:MNPR) Sees Unusually-High Trading VolumeHere's What Happened - MarketBeat
How Monopar Therapeutics Inc. (1IY0) stock correlates with oil markets2025 Investor Takeaways & Reliable Volume Spike Alerts - Newser
Can Monopar Therapeutics Inc. (1IY0) stock stage a strong rebound this quarterRecession Risk & Risk Controlled Stock Alerts - Newser
Is Monopar Therapeutics Inc. (1IY0) stock worth buying before Fed actionMarket Activity Report & High Accuracy Investment Signals - Newser
Is Monopar Therapeutics Inc. stock a safe investment in uncertain markets2025 Support & Resistance & Entry Point Strategy Guides - moha.gov.vn
Monopar Therapeutics Inc Stock Analysis and ForecastContrarian Investment Ideas & Free Rapid Portfolio Appreciation - earlytimes.in
Monopar Therapeutics (NASDAQ:MNPR) Shares Down 4%Time to Sell? - MarketBeat
Monopar Therapeutics (NASDAQ:MNPR) Shares Gap UpHere's What Happened - MarketBeat
Monopar Therapeutics Unveils Promising Phase 2 Study Results - MSN
Monopar Therapeutics Reports Third Quarter 2025 Financial Results and Recent Developments - ADVFN
Trading Systems Reacting to (MNPR) Volatility - news.stocktradersdaily.com
Monopar Therapeutics Inc. (MNPR) Stock Price, News, Quote & History - Yahoo! Finance Canada
Is There An Opportunity With Monopar Therapeutics Inc.'s (NASDAQ:MNPR) 46% Undervaluation? - simplywall.st
Is Monopar Therapeutics Inc. (NASDAQ:MNPR) Trading At A 46% Discount? - Yahoo Finance
Monopar Therapeutics Shares Surge in Volatile Friday Session - Ad-hoc-news.de
Is Monopar Therapeutics Inc. stock a top momentum playTrade Signal Summary & Safe Entry Trade Signal Reports - newser.com
How geopolitical tensions affect Monopar Therapeutics Inc. stock2025 Institutional Moves & Growth Focused Investment Plans - newser.com
Will Monopar Therapeutics Inc. stock outperform Dow Jones indexMarket Volume Report & High Win Rate Trade Tips - newser.com
Why Monopar Therapeutics Inc. (1IY0) stock could be top winnerJuly 2025 Rallies & Long-Term Investment Growth Plans - newser.com
Why millennials buy Monopar Therapeutics Inc. (1IY0) stock2025 Support & Resistance & Free Fast Gain Swing Trade Alerts - newser.com
How Monopar Therapeutics Inc. (1IY0) stock expands through international marketsJuly 2025 Market Mood & Momentum Based Trading Ideas - newser.com
Can Monopar Therapeutics Inc. stock sustain market leadershipJuly 2025 Price Swings & Verified Trade Idea Suggestions - newser.com
Monopar Therapeutics Inc Stock (MNPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Monopar Therapeutics Inc Stock (MNPR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| KLAUSNER ARTHUR J | Director |
Dec 18 '25 |
Sale |
67.15 |
5,121 |
343,889 |
8,762 |
| Tactic Pharma LLC | 10% Owner |
Sep 24 '25 |
Sale |
63.61 |
550,229 |
34,999,957 |
272,026 |
| Tsuchimoto Kim R | Director |
Jul 14 '25 |
Sale |
40.00 |
8,904 |
356,171 |
11,486 |
| STARR CHRISTOPHER M | Director |
Jul 14 '25 |
Sale |
40.00 |
16,800 |
672,020 |
5,173 |
| Robinson Chandler | Chief Executive Officer |
Jul 14 '25 |
Sale |
40.00 |
16,800 |
672,020 |
73,472 |
0.08%
1.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):